Related references
Note: Only part of the references are listed.Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma
Staci L. Haney et al.
DRUG DEVELOPMENT RESEARCH (2023)
Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase
Hiu-Fung Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Staci L. Haney et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
The mevalonate pathway is an actionable vulnerability oft(4;14)-positive multiple myeloma
Joseph Longo et al.
LEUKEMIA (2021)
In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway
Staci L. Haney et al.
PHARMACOLOGICAL RESEARCH (2021)
Pathway-Directed Therapy in Multiple Myeloma
Lukas John et al.
CANCERS (2021)
Immunotherapy of Multiple Myeloma: Promise and Challenges
Hanley N. Abramson
IMMUNOTARGETS AND THERAPY (2021)
Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients
Elsa Branvall et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis
Ben Ponvilawan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
A SNARE geranylgeranyltransferase essential for the organization of the Golgi apparatus
Ryutaro Shirakawa et al.
EMBO JOURNAL (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma
Staci L. Haney et al.
ONCOGENE (2019)
GGTase3 is a newly identified geranylgeranyltransferase targeting a ubiquitin ligase
Shafi Kuchay et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors
Thomas B. Karasic et al.
TARGETED ONCOLOGY (2019)
In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution
Staci L. Haney et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells
Xianqi Feng et al.
MEDICAL SCIENCE MONITOR (2019)
Novel benzimidazole phosphonates as potential inhibitors of protein prenylation
Nazmul H. Bhuiyan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors
Robert A. Matthiesen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors
Cyrus M. Lacbay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Statin use and risk of multiple myeloma: An analysis from the cancer research network
Mara M. Epstein et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Identification of the Privileged Position in the Imidazo[1,2-a]pyridine Ring of Phosphonocarboxylates for Development of Rab Geranylgeranyl Transferase (RGGT) Inhibitors
Aleksandra Kazmierczak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase
Cheryl Allen et al.
MOLECULAR PHARMACOLOGY (2017)
Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation
Sherry S. Agabiti et al.
CELL DEATH & DISEASE (2017)
Risk of multiple myeloma in a case-spouse study
Gabriella Andreotti et al.
LEUKEMIA & LYMPHOMA (2016)
Protease-Resistant and Cell-Permeable Double-Stapled Peptides Targeting the Rab8a GTPase
Philipp M. Cromm et al.
ACS CHEMICAL BIOLOGY (2016)
Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells
Masanobu Tsubaki et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Statins Are Associated With Reduced Mortality in Multiple Myeloma
Kristen Marie Sanfilippo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates
Robert A. Matthiesen et al.
JOURNAL OF ORGANIC CHEMISTRY (2016)
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
Heleen. H. Van Acker et al.
PHARMACOLOGY & THERAPEUTICS (2016)
N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation
Xiang Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase
Veronica S. Wills et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
The role of P-glycoprotein in drug resistance in multiple myeloma
Joseph Abraham et al.
LEUKEMIA & LYMPHOMA (2015)
Triazole-based inhibitors of geranylgeranyltransferase II
Xiang Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition
Adrianna Slawinska-Brych et al.
LEUKEMIA RESEARCH (2013)
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
Gareth J. Morgan et al.
BLOOD (2012)
Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Martin Thurnher et al.
CLINICAL CANCER RESEARCH (2012)
Development of Selective, Potent RabGGTase Inhibitors
E. Anouk Stigter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway
Masanobu Tsubaki et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
Marek Hus et al.
ANNALS OF HEMATOLOGY (2011)
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase
Verena Stresing et al.
BONE (2011)
Involvement of Chk1-Cdc25A-cyclin A/CDk2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells
Yong-Sheng Tu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells
Sarah A. Holstein et al.
LEUKEMIA RESEARCH (2011)
The 'invisible hand': regulation of RHO GTPases by RHOGDIs
Rafael Garcia-Mata et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines
Takayuki Tamura et al.
ONCOLOGY REPORTS (2011)
Targeting protein prenylation for cancer therapy
Norbert Berndt et al.
NATURE REVIEWS CANCER (2011)
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma
James W. Clendening et al.
BLOOD (2010)
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
Ebenezer David et al.
BLOOD (2010)
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives
Qian Zhou et al.
CIRCULATION JOURNAL (2010)
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation
Andreas Guenther et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
RHO GTPase Signaling for Axon Extension: Is Prenylation Important?
Filsy Samuel et al.
MOLECULAR NEUROBIOLOGY (2010)
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells
Sarah A. Holstein et al.
LEUKEMIA RESEARCH (2010)
The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro
Laura M. Mitrofan et al.
BONE (2009)
A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma
T. E. Sondergaard et al.
HEMATOLOGICAL ONCOLOGY (2009)
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma
Ellen van der Spek et al.
LEUKEMIA RESEARCH (2009)
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway
Dominik Fuchs et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease
Michelle A. Lawson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells
Yun Dai et al.
BLOOD (2008)
Structures of RabGGTase-substrate/product complexes provide insights into the evolution of protein prenylation
Zhong Guo et al.
EMBO JOURNAL (2008)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
The endoplasmic reticulum and the unfolded protein response
Jyoti D. Malhotra et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2007)
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma
Ralf Schmidmaier et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation
Yun Dai et al.
BLOOD (2007)
Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation
Mona A. Maalouf et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells
Anke J. Roelofs et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies
SA Holstein et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia
N Yanamandra et al.
CLINICAL CANCER RESEARCH (2006)
Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells
MA Morgan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo
FP Coxon et al.
BONE (2005)
Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells
P Cafforio et al.
CARCINOGENESIS (2005)
Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
S Mariani et al.
LEUKEMIA (2005)
The Ras superfamily at a glance
K Wennerberg et al.
JOURNAL OF CELL SCIENCE (2005)
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
M Alsina et al.
BLOOD (2004)
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
R Kurzrock et al.
BLOOD (2003)
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents
SJ DeSolms et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Membrane targeting of Rab GTPases is influenced by the prenylation motif
AQ Gomes et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells
SCE Bolick et al.
LEUKEMIA (2003)
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
NWCJ van de Donk et al.
BLOOD (2003)
Farnesyl protein transferase inhibitor ZARNESTRA (TM) R115777 - History of a discovery
M Venet et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2003)
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages
FP Coxon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Farnesyl transferase inhibitors - a novel therapy for breast cancer
SRD Johnston et al.
ENDOCRINE-RELATED CANCER (2001)
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
JE Karp et al.
BLOOD (2001)
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
FP Coxon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
